What is it about?
CYP1A2, CYP2C9, CYP2C19 and CYP2D6 gene polymorphisms were characterized using high resolution melting analysis (HRMA) in follow-up patients in psychiatry clinic as a preliminary preparation for personalized medicine.
Photo by freestocks.org on Unsplash
Why is it important?
This was a first study in Cukurova Province the South Part of Turkey which demonstrates the characterization of drug metabolizing enzyme gene polymorphisms using high resolution melting analysis (HRMA) in psychiatry patients.
Read the Original
This page is a summary of: Characterization CYP1A2, CYP2C9, CYP2C19 and CYP2D6 polymorphisms using HRMA in Psychiatry patients with schizophrenia and bipolar disease for personalized medicine, Combinatorial Chemistry & High Throughput Screening, June 2018, Bentham Science Publishers, DOI: 10.2174/1386207321666180619164726.
You can read the full text:
The following have contributed to this page